Charlottesville, Virginia-based Navion Neurosciences, Inc. announced first closing of a USD 10.8 million seed financing round to advance precision sodium-channel therapeutics for genetic epilepsy and chronic neuropathic pain, conditions where existing treatments are limited by the poor therapeutic window associated with broad sodium-channel modulation.
The Angelini Lumira Biosciences Fund led the round, with participation from 3B Future Health Fund, UVA LVG Seed Fund, Virginia Innovation Partnership Corporation, VTC Innovation Fund, and Navion management. Gerry Brunk, Managing Partner at Lumira Ventures, cited the team's demonstrated experience in the ion-channel field and the company's application of AI-enabled tools as factors in the investment decision. Proceeds will support the company's lead programs in genetic epilepsy and neuropathic pain and continued development of its NaViGATion discovery platform.
Navion's platform integrates AI-enabled chemistry, structural biology, human disease biology, and ion-channel expertise with the aim of achieving more precise modulation of disease-relevant sodium-channel activity. The company said the approach is designed to improve the therapeutic window associated with traditional agents that broadly suppress sodium-channel function — a limitation that has historically constrained the clinical utility of this drug class in both epilepsy and pain.